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ORIGINAL ARTICLE Reproductive genetics
A reduced size of the ovarian follicle
pool is associated with an increased risk
of a trisomic pregnancy in IVF-treated
women
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background: The increased risk of a trisomic pregnancy with a woman’s age arises from an increased rate of meiotic non-disjunction in
the oocytes. It has been hypothesized that the increase in meiotic errors is related to the decreasing number of oocytes with age. Our aim
was to assess the relation between trisomic pregnancy and three parameters of oocyte quantity.
methods: In a Dutch nationwide database on in vitro fertilization (IVF) treatment from 1983 to 1995, we identiﬁed 28 women with a
trisomic pregnancy conceived via or within 1 year from IVF treatment. We selected ﬁve age-matched controls with a healthy child for
each trisomy case. We performed a case–control study to examine whether trisomy cases more often had a history of ovarian surgery
and a lower response to ovarian hyperstimulation than controls. Subsequently, cases and controls were followed to compare the incidence
of signs of menopause at the end of the study period as self-reported by questionnaire.
results: Logistic regression analysis showed an association between trisomic pregnancy and a history of ovarian surgery [odds ratio (OR)
3.3; 95% conﬁdence interval (CI): 1.0–10.5; P ¼ 0.04] and between trisomic pregnancy and retrieval of 4 oocytes during IVF treatment
(OR 4.0; 95% CI: 1.4–11.5; P ¼ 0.01). The adjusted OR for signs of menopause associated with trisomic pregnancy was 5.7 (95% CI: 1.1–
29.9; P ¼ 0.04).
conclusions: Our results suggest that IVF-treated women with a reduced ovarian follicle pool are at increased risk of a trisomic preg-
nancy, independent of their age. Our ﬁndings support the hypothesis that follicle pool size and not chronological age determines a woman’s
trisomy risk. Since a questionnaire was used, we cannot fully exclude the possibility of selection bias in this study.
Key words: trisomic pregnancy / trisomy / ovarian reserve / poor response / in vitro fertilization
Introduction
The increased risk of a trisomic pregnancy with a woman’s age arises
from an increased rate of meiotic non-disjunction in the oocytes
(Hassold et al., 1996; Eichenlaub-Ritter, 1998). It has been
hypothesized that this increase in meiotic errors is related to the
decreasing number of oocytes with age (Henderson and Edwards,
1968; Brook et al., 1984; Warburton, 1989, 2005; Zheng and Byers,
1992). Selection of oocytes may become impaired when less
oocytes are available (limited pool hypothesis) or physiological
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changes accompanying follicle loss, such as the increase in
follicle-stimulating hormone, may affect oocyte integrity (Warburton,
1989, 2005; Dursun et al., 2005; McTavish et al., 2007).
The quantitative size of the ovarian follicle pool is inversely related
to age, but shows substantial variation among peers (Te Velde and
Pearson, 2002). This inter-individual variation in follicle pool size is
reﬂected in the wide age range for the onset of menopause, the
event that indicates imminent depletion of the follicle pool (Te
Velde et al., 1998). In addition to ageing, iatrogenic intervention,
such as ovarian surgery, may also reduce the follicle pool. The size
of the follicle pool during the fertile period can be estimated by
so-called ovarian reserve tests, i.e. hormonal or sonographic tests,
such as follicle-stimulating hormone (FSH), anti-Mu¨llerian hormone
or antral follicle count (Broekmans et al., 1998, 2006). The number
of follicles that develop in response to ovarian hyperstimulation
during in vitro fertilization (IVF) treatment can be regarded as a
dynamic ovarian reserve test (Broekmans et al., 2006).
If indeed the effect of maternal age on trisomy risk is explained by
the decrease in follicle number, one would expect to ﬁnd an associ-
ation between the above parameters of oocyte quantity and trisomy
risk, independent of female age. We addressed this issue in a Dutch
nationwide cohort of women undergoing IVF treatment. We hypoth-
esized that the risk of a trisomic pregnancy is elevated in women
with a reduced size of the ovarian follicle pool, independent of
their age. Therefore, we performed a case–control study to
examine whether women with a trisomic pregnancy more often
had a history of ovarian surgery and a lower response to ovarian
hyperstimulation. Subsequently, we followed these women to
assess whether the trisomy cases had more often reached menopau-
sal transition or menopause at the end of the study period than the
controls.
Materials and Methods
The present study is a part of the OMEGA project, a large retrospective
cohort study in the Netherlands originally designed to assess the effects
of ovarian hyperstimulation in IVF treatment on the risk of
hormone-related cancers. The study population, study procedures and
data collection methods have been described in detail elsewhere (De
Boer et al., 2003; Klip et al., 2003). In brief, all subfertile women starting
at least one IVF cycle in the Netherlands between 1 January 1983 (the
national start of IVF treatment) and 1 January 1995 were retrospectively
included in the cohort (n ¼ 19 840). The institutional review boards from
all the participating IVF centres approved the study protocol. From 1997
to 1999, questionnaires on risk factors were sent to all women who
could be traced, including detailed questions on reproductive history, life-
style and health problems in their children (response rate of 71%). In a
form attached to the questionnaire, women could give their permission
to search their medical ﬁles. Trained research assistants retrieved data
on medical and reproductive history, subfertility characteristics and
course and outcome of treatment from the medical ﬁles of the women
who had given written permission to do so. Owing to limited project
funding data collection could only be completed for 75% of these
women. The women with missing medical ﬁle data did not represent a
subgroup with ﬁles or data that were for any reason especially hard to
retrieve; data collection was completed per participating IVF clinic
before moving on to the next clinic and therefore from some clinics
no data were collected at all.
We used a case–control design to assess the association between
ovarian surgery and ovarian response to IVF treatment and trisomic preg-
nancy. Cases were women with a trisomic pregnancy; controls were
women with a live birth without a trisomy. Subsequently, we followed
these women to examine whether cases with a trisomic pregnancy had
an increased risk of natural menopause or menopausal transition at the
end of the study period compared with controls. We searched for
cases of trisomic pregnancy in the complete OMEGA database. In data
from both medical ﬁles and questionnaires, we assessed the variables
reporting pregnancy outcome, including open ﬁelds with comments on
pregnancies and health problems in children. We selected all women
with comments possibly related to trisomic pregnancy and all those with
an induced abortion or stillbirth for which no explanation was recorded.
For all selected women who had given their written permission to do
so, we searched the original medical records to see if a trisomic pregnancy
had been documented; in total 215 medical ﬁles were searched. Trisomic
pregnancies, conﬁrmed by karyotype, were selected for analysis if the
pregnancy resulted from IVF treatment or was naturally conceived
within a year before or after IVF treatment. We decided beforehand to
include naturally conceived trisomic pregnancies in order to maximize
our sample size. We chose an (arbitrary) cut-off of 1 year, assuming
that the ovarian response at the nearest IVF treatment would be represen-
tative for the ovarian status at the time of conception within 1 year. Sex
chromosomal aneuploidies were excluded. In total, we identiﬁed
28 cases of trisomic pregnancy fulﬁlling our criteria. Next to non-
disjunction in the oocyte, in a minority of cases (,10%) trisomies may
be caused by an unbalanced translocation or may be of paternal origin
(Freeman et al., 2007). We did not conﬁrm the origin of the trisomic preg-
nancies in this study and no information on the karyotype of the couples
was available. None of the women contributed more than one case of tri-
somic pregnancy.
For each trisomy case, we selected ﬁve individually matched controls
who did not have a trisomic pregnancy from the same database. The con-
trols were women who conceived via IVF treatment or within a year
before or after IVF treatment and had a live birth. They were matched
for age at the time of IVF treatment, mode of conception, period of IVF
treatment and fertility centre. The IVF cycle resulting in the trisomic or
control pregnancy or, in the case of natural conception, the IVF cycle
nearest to the conception of the trisomic or control pregnancy is hereafter
referred to as the ‘index IVF cycle’.
For cases and controls, we retrieved subfertility and lifestyle character-
istics from questionnaire and medical ﬁle data. Data on ovarian surgery
were compared with the data from the Dutch nationwide network and
registry of histo- and cytopathology (PALGA) for conﬁrmation, where
possible. Ovarian surgery was recorded only if performed before the
start of the index IVF cycle. Ovarian response during the index IVF cycle
was deﬁned as the number of oocytes retrieved at follicle aspiration.
A poor response was deﬁned as an oocyte yield of 0–3 oocytes. In pre-
vious studies employing this frequently used cut-off value, it was shown
that women with a poor response have an increased risk of early meno-
pause (De Boer et al., 2002, 2003; Lawson et al., 2003). Age was
deﬁned as the woman’s age at the start of the index IVF cycle. For
body mass index and smoking habits, we used the self-reported values
in the questionnaire. Total medication dose was deﬁned as the total
number of ampoules of recombinant FSH or human menopausal gonado-
trophin used in the index IVF cycle. We had to replace 12 of the original
controls, since 11 controls had an unknown response to the index IVF
cycle and 1 control reported a post-partum death without explanation
and had not given permission to search the medical ﬁle.
For the second analysis, we studied data from the questionnaire on the
length and regularity of the menstrual cycle at the ﬁrst visit to the fertility
clinic and at the moment of ﬁlling in the questionnaire. The median time
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between the index IVF cycle and ﬁlling in the questionnaire was 4.1 years
(range 0.6–11.9 years). We selected the women who reported a regular
cycle (i.e. next cycle predictable within 4 days) with a cycle length 21–35
days at their ﬁrst visit to the fertility clinic. Next, we determined their
menopausal status at the time of the questionnaire. Natural menopause
was deﬁned as the spontaneous absence of vaginal bleeding for at least
1 year, except if due to pregnancy or breastfeeding. Menopausal
transition was deﬁned as a change in cycle pattern to an irregular cycle
(i.e. next cycle not predictable within 4 days) and/or a change in cycle
length to ,21 or .35 days. Those whose last menstruation dated
3–11 months before completion of the questionnaire were also regarded
as being in menopausal transition (if not pregnant or breastfeeding). The
use of hormonal replacement therapy (HRT) was considered as a sign of
menopause, as its use in the Netherlands is generally restricted to
women after menopause (De Jong-van den Berg et al., 2006). Women
with natural menopause, menopausal transition and use of HRT were
combined into one category having ‘signs of menopause’, whereas
those reporting a regular cycle between 21 and 35 days at the time of
the questionnaire were considered premenopausal. Women using oral
contraceptives at the time of the questionnaire were excluded from
analysis, as were women with a history of hysterectomy or chemo- or
radiotherapy.
The original matching between cases and controls was not taken into
account for the analysis on menopausal status. Cases and controls were
independently selected for this analysis if their data were complete and
they met our inclusion criteria.
We used multivariate conditional logistic regression analysis to calculate
the odds ratios (ORs) for trisomic pregnancy associated with a history of
ovarian surgery and response to IVF treatment. We analysed the variable
ovarian response in three different ways, i.e. linear, ordinal and dichoto-
mous, in order to be able to identify both a possible linear or non-linear
relation. Response to IVF treatment was divided into three categories (ter-
tiles); smaller categories could result in inaccurate estimates due to limited
sample size. Ovarian response was dichotomized into poor response yes
or no. Values for smoking habits, body mass index and total medication
dose were not known for all cases and controls. If a value for a case
was missing, the case and its matched controls were removed from the
analysis. If a value for a control was missing, it was assigned the value of
the respective case; thus the control concerned did not contribute to
the risk estimate (Rookus and Van Leeuwen, 1994). Each potential con-
founder was added separately to the logistic model. If this resulted in a
change in OR of 10% or more, the confounder was included in the
model (Rothman and Greenland, 1998). This process was repeated until
no other confounders were identiﬁed.
Second, we used unconditional logistic regression analysis to examine
whether women with a trisomic pregnancy more often showed signs of
menopause at the time of ﬁlling in the questionnaire at the end of the
study period than controls. This analysis may be regarded as a follow-up
study of the case–control cohort, deﬁned by clear eligibility criteria.
Matching is not relevant in this kind of analysis and was not taken into
account. We calculated the OR for signs of menopause associated with
trisomic pregnancy and evaluated potential confounders as described
above. A history of ovarian surgery and response to IVF treatment were
not regarded as potential confounders because both parameters are
related to age at menopause (Melica et al., 1995; De Boer et al., 2003;
Lawson et al., 2003). Since we hypothesized that women with a history
of ovarian surgery or a low response to IVF treatment have an increased
risk of trisomic pregnancy, correction for these variables would lead to
underestimating the true relation between trisomic pregnancy and signs
of menopause. A P-value of ,0.05 was considered statistically signiﬁcant.
Data were analysed with SPSS 14.0 (SPSS Inc., Chicago, IL, USA) and
EGRET 2.0.31 (Cytel Software, Cambridge, MA, USA).
Results
In total, we identiﬁed 28 cases of trisomic pregnancy conceived via or
within 1 year before or after IVF treatment. For each case, ﬁve con-
trols were selected (n ¼ 140). Median age of the cases at the time
of the index IVF cycle was 37.9 years. Among the trisomic pregnancies
were 24 cases of trisomy 21, 3 cases of trisomy 18 and 1 case of
trisomy 13. In 8 cases the pregnancy resulted in a live birth (all
trisomy 21), in 2 cases a stillbirth was reported and 18 trisomic preg-
nancies were terminated after prenatal diagnosis. In four cases, the
fetus with trisomy was one of dizygotic twins. In 26 cases, the trisomic
pregnancy followed IVF treatment, whereas two trisomic pregnancies
resulted from spontaneous conception.
Parameters of oocyte quantity, subfertility and lifestyle character-
istics of cases and controls and the ORs for trisomic pregnancy are
shown in Table I. Details on ovarian surgery are given in Table II.
The OR for trisomic pregnancy associated with a history of ovarian
surgery was 3.3 [95% conﬁdence interval (CI): 1.0–10.5; P ¼ 0.04].
Adding the variables body mass index, smoking habits, total medi-
cation dose and multiple pregnancy to the regression model did not
materially affect the OR.
The OR for trisomic pregnancy associated with 4 retrieved
oocytes was 4.0 (95% CI: 1.4–11.5; P ¼ 0.01; reference category
5 oocytes). The OR for trisomic pregnancy associated with poor
response (3 retrieved oocytes) was 2.7 (95% CI: 0.7–10.7; P ¼
0.15). Adding the potential confounders did not substantially change
the ORs for trisomic pregnancy associated with oocyte number.
Figure 1 shows the ﬂowchart of cases and controls suitable for
analysis of menopausal status. Of the original 168 women, 72 met
our criteria. The proportion of cases with complete data on menopau-
sal status (12 of 28; 43%) was the same as the proportion of controls
available for this analysis (60 of 140; 43%). Median age at the time of
ﬁlling in the questionnaire was 42.4 years (range 33.3–51.4 years). Of
the nine women with signs of menopause, four were cases (33%) and
ﬁve controls (8.3%). The unadjusted OR for signs of menopause
associated with trisomic pregnancy was 5.5 (95% CI: 1.2–24.9; P ¼
0.03). Age and smoking habits at the time of completing the question-
naire were identiﬁed as confounders. The adjusted OR for signs of
menopause associated with trisomic pregnancy was 5.7 (95% CI:
1.1–29.9; P ¼ 0.04).
All analyses were repeated using the 12 original controls that had
been replaced and showed comparable results. Similarly, the exclusion
of the two naturally conceived cases and their controls did not mate-
rially affect the odds ratios; if excluded from the analysis, the OR for
trisomic pregnancy associated with ovarian surgery was 2.6 (95% CI:
0.8–9.0; P ¼ 0.13), the OR for trisomic pregnancy associated with
4 retrieved oocytes was 4.9 (95% CI: 1.6–15.2; P, 0.01) and the
adjusted OR for signs of menopause associated with trisomic
pregnancy was 8.6 (95% CI: 1.4–52.4, P ¼ 0.02).
Discussion
The results of our study point to a relation between trisomic preg-
nancy and reduced follicle pool size, independent of a woman’s age.
Trisomy cases more often had a history of ovarian surgery and low
ovarian response to IVF treatment and more often showed signs of
menopause at follow-up than controls.
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Table I ORs of trisomic pregnancy associated with parameters of oocyte quantity, subfertility and lifestyle characteristics
n Casesa [n 5 28;
median (10th–90th
percentile) or no. (%)]
Controlsa [n5 140;
median (10th–90th





Parameters of oocyte quantity
History of ovarian surgery before
IVF cycle
168
Yes 5 (17.9) 7 (5.7) 3.3 (1.0–10.5) 0.04
No 23 (82.1) 133 (94.3) 1.0 (reference) —
Total number of oocytes retrieved
in IVF cycle
168 6.5 (2–19) 8 (4–18) 1.0 (0.9–1.0) 0.32
Number of retrieved oocytes in
categories
168
1–4 9 (32.2) 17 (12.1) 3.7 (1.2–11.7) 0.03
5–8 8 (28.6) 57 (40.7) 0.9 (0.3–2.3) 0.76
9 11 (39.3) 66 (47.1) 1.0 (reference)
Poor response in IVF cycle 168
Yes (3 oocytes) 4 (14.3) 9 (6.4) 2.7 (0.7–10.7) 0.15
No (4 oocytes) 24 (85.7) 131 (93.6) 1.0 (reference) -
Subfertility and lifestyle characteristics
Smoking at time of IVF treatment 136
Yes 10 (40.0) 32 (28.8) 1.5 (0.5–3.9)c 0.45
No 15 (60.0) 79 (71.2) 1.0 (reference)
Body mass index 139
25 kg/m2 19 (76.0) 81 (71.1) 1.0 (reference)
.25 kg/m2 6 (24.0) 33 (28.9) 0.6 (0.2–1.6)c 0.31
Multiple pregnancy 168
Yes 4 (14.3) 22 (15.7) 0.9 (0.3–2.8) 0.85
No 24 (85.7) 118 (84.3) 1.0 (reference)
Total no. of ampoules HMG or
rFSHd
153 27 (17.5–40.5) 24 (15–40) 1.0 (0.9–1.1)c 0.77
aCases and controls were matched for age at the time of IVF treatment, mode of conception, period of IVF treatment and fertility centre.
bThe ORs shown are crude ORs. No confounders of the associations between trisomic pregnancy and the various parameters of oocyte quantity were identiﬁed: adding the variables body
mass index, smoking habits, total medication dose and multiple pregnancy to the regression model did not materially affect the ORs.
cFor these analyses, values of 3 (smoking and body mass index) or 4 cases (medication dose) were unknown; these cases and their matched controls were excluded. Values were unknown
for 18 (smoking), 19 (body mass index) and 7 (medication dose) of the remaining controls and substituted by the values of the cases they were matched to.
dHMG, human menopausal gonadotrophin; rFSH, recombinant follicle-stimulating hormone.
.............................................................................................................................................................................................
Table II Characteristics of ovarian surgery
Type of ovarian surgery Reason for ovarian surgery Age at surgery (in years)
Trisomy cases (n ¼ 5) Unilateral adnexal extirpation Functional cyst 30.0
Unilateral adnexal extirpation Unknown 23.1
Unilateral ovariectomy Benign cystic teratoma 18.4
Cystectomy Endometrioma 34.6
Cystectomy Unknown 25.5
Controls (n ¼ 8) Unilateral adnexal extirpation Tubal-ovarian abscess 29.1
Unilateral adnexal extirpation Adhesions 36.2
Unilateral ovariectomy Adnexal torsion 33.8
Cystectomy Functional cyst 28.9
Cystectomy Functional cyst 36.3
Cystectomy Functional cyst 32.0
Cystectomy Corpus luteum cyst 34.1
Wedge resection Polycystic ovarian syndrome 21.9
Follicle pool size and trisomic pregnancy 555
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The phenomenon of female reproductive ageing is attributed to a
decline in both the quantity and the quality of the remaining oocytes
(Te Velde and Pearson, 2002; Baird et al., 2005). The decrease in
oocyte quantity eventually leads to menopause; the decrease in
oocyte quality is reﬂected in the age-related increase in meiotic
errors. Loss of oocyte quantity and quality could progress indepen-
dently of each other. The number of follicles present in the ovaries
at any time is most likely determined by the original size of the fetal
follicle pool and the rate of atresia of this pool. Oocyte quality may
be determined by biological damage accumulating over time.
However, some theories do suggest a relation between oocyte quan-
tity and quality. The ‘limited pool hypothesis’ states that the process of
oocyte selection might become impaired if the number of oocytes to
select from is decreased (Warburton, 2005). Furthermore, as the
number of follicles declines, the endocrine and paracrine environment
of the remaining oocytes may hypothetically harm their quality, for
example, by increased levels of FSH (Dursun et al., 2005; Warburton,
2005; McTavish et al., 2007). Our ﬁndings suggest a relation between
follicle pool size and trisomy risk, independent of a woman’s age, and
thus support a relation between oocyte quantity and quality. The fact
that all three parameters, i.e. ovarian surgery, oocyte number
retrieved in IVF treatment and signs of menopause, point towards
an increased trisomy risk with reduced follicle pool size is remarkable,
as is the fact that, despite the small numbers involved, several associ-
ations reached statistical signiﬁcance.
In this study, a low oocyte yield of 4 oocytes was statistically sig-
niﬁcantly associated with an increased risk of a trisomic pregnancy.
Interestingly, we did not ﬁnd a linear association between trisomic
pregnancy and number of retrieved oocytes when this was analysed
as a continuous variable, nor when it was categorized in tertiles
(4, 5–8 and 9 oocytes, respectively). This non-linear relation is
not unexpected. For instance, the relation between female age and
aneuploidy rate is not linear either, nor is the relation between age
and follicle pool size (Hassold and Chiu, 1985; Faddy et al., 1992;
Hassold and Hunt, 2001; Hansen et al., 2008).
Interpretation of the results could be challenged by the limitations
of the parameters of oocyte quantity used. We identiﬁed a history
of ovarian surgery, an iatrogenic depletion of the follicle pool, as a
risk factor for trisomic pregnancy. We cannot rule out the possibility
that the ovarian pathology leading to the surgery accounted for the
decrease in oocyte quality, though the indications for ovarian
surgery show a wide variation.
Second, an oocyte yield of 4 oocytes and an oocyte yield of 3
oocytes at IVF treatment were both associated with an increased risk
of a trisomic pregnancy, but for 3 oocytes this association was not
statistically signiﬁcant, probably due to the small numbers involved.
We considered the OMEGA database to be suitable for this research
question despite the fact that medication protocols and laboratory
procedures have developed considerably since its inception. No
actual improvement of the outcome of IVF treatment in low respon-
ders has been shown as a result of these changes (Loutradis et al.,
2003; Ubaldi et al., 2005; Shanbhag et al., 2007), and poor response
remains one of the chief challenges in today’s reproductive medicine.
For our third parameter of oocyte quantity, signs of menopause, we
included women with a change in cycle pattern suggesting menopausal
transition and women using HRT. We decided beforehand not only to
include women that actually reached menopause, since the median
time between ﬁlling in the questionnaire (from which the data on
menopausal status were obtained) and the IVF cycle studied was
only 4.1 years. We did not expect a sufﬁcient number of women to
be post-menopausal in this short period of time to allow any meaning-
ful analysis: several years before menopause occurs, fertility is already
severely impaired, whereas these women actually conceived after the
index IVF cycle. However, it turned out that none of the eligible cases
and controls had in fact reached natural menopause, which may be
regarded as the ultimate parameter for oocyte quantity. The pro-
portion of subjects in our analysis of menopausal status was only
43% of the total study population. In this analysis, the original matching
of cases and controls was not taken into account.
We cannot exclude the possibility that the 71% response rate to
the questionnaire may have led to selection bias. Trisomic and
control pregnancies that were not reported in the questionnaire and
not mentioned in the medical ﬁle data (e.g. from the non-represented
clinics) were missed in the present study. The question is whether
women with a trisomic pregnancy and reduced follicle pool size
were less or more likely to respond than women with a control preg-
nancy and reduced follicle pool size. We assume this is not the case
since we cannot think of a plausible reason why, but cannot rule
out the possibility of selection bias.
Finally, with 28 cases the number of subjects in our matched case–
control study was limited, despite the nationwide database of IVF
patients available. Fertility is already impaired years before menopause
is reached and poor responders in IVF treatment are known to have
low pregnancy chances (Saldeen et al., 2007). If a low number of
remaining oocytes is indeed related to an increased trisomy risk,
larger samples will be hard to obtain.
The relation between trisomic pregnancy and parameters of oocyte
quantity has been studied previously. Freeman et al. (2000) performed
a case–control study and found, in line with our results, that women
with a child with trisomy 21 signiﬁcantly more often had a history of
ovarian surgery or congenital absence of an ovary compared with con-
trols (7 of 189 cases versus 1 of 329 controls). The ﬁndings also
Figure 1 Flow chart of patients eligible for analysis of menopausal
status.
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correspond to the mouse studies of Brook et al. (1984), which
showed an increased incidence of aneuploid embryos in ageing mice
after unilateral ovariectomy. Kline et al. compared 111 women with
a spontaneous miscarriage with a trisomic karyotype with 226
women with a healthy live birth and 157 women with a chromoso-
mally normal pregnancy loss. Compared with the other two groups,
the women with a history of trisomic pregnancy entered menopause
approximately 1 year earlier (0.96 years, 95% CI: 20.18 to 2.10)
(Kline et al., 2000). Bartmann et al. (2005) found that 104 mothers
of a child with Down syndrome entered menopause 0.7 years
earlier than 121 control mothers with a healthy child. In both
studies, the difference in menopausal age between cases and controls
was not statistically signiﬁcant. To our knowledge, the relation
between ovarian response to IVF treatment and trisomy risk has
not been studied before.
Well-known parameters for oocyte quantity that were not available
in the present study are endocrine and sonographic ovarian reserve
tests. Van Montfrans et al. (1999, 2002) found that mothers of a
child with trisomy 21 (n ¼ 118) had signiﬁcantly higher levels of FSH
and lower levels of inhibin B than age-matched controls (n ¼ 102).
Kline et al. did not ﬁnd statistical differences in antral follicle count,
FSH or inhibin B levels between women with a spontaneous miscar-
riage of a trisomic pregnancy (n ¼ 54) compared with women with
a spontaneous miscarriage due to other causes (n ¼ 45) or with a
live birth (n ¼ 65) (Kline et al., 2004). Nasseri et al. karyotyped mis-
carriage tissue and found higher FSH and/or estradiol levels in
women with an aneuploid spontaneous miscarriage (n ¼ 44) than in
women with a euploid spontaneous miscarriage (n ¼ 34) (Nasseri
et al., 1999). Anti-Mu¨llerian hormone (AMH) is now considered the
most promising marker of follicle pool size (Van Rooij et al., 2005;
Visser et al., 2006), but one study comparing AMH levels in samples
from a prenatal screening program found no statistically signiﬁcant
difference between 25 women with a Down syndrome pregnancy
compared with 125 matched controls (Seifer et al., 2007).
In conclusion, despite the absence of general consensus, our results
point to a relation between trisomic pregnancy and a reduced size of
the ovarian follicle pool, independent of a woman’s age. Our ﬁndings
support a relation between oocyte quantity and quality and indicate
that the size of the follicle pool and not chronological age may deter-
mine a woman’s trisomy risk. Since we used three different par-
ameters of oocyte quantity that all support this relation, this is
unlikely to be an accidental ﬁnding. However, since a questionnaire
was used, we cannot fully exclude the possibility of selection bias.
Moreover, results from studies performed in an IVF population
cannot simply be extrapolated into the general population. The risk
of a trisomic pregnancy for IVF patients may not be comparable to
that in the general population, for instance, the effect of embryo selec-
tion on trisomic risk is unclear. Our results need conﬁrmation in
another IVF cohort, before the clinical use of parameters of oocyte
quantity for the assessment of trisomy risk can be considered in IVF
patients.
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